Every material Form 8-K abrdn World Healthcare Fund has filed with the SEC since October 19, 2015, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Deloitte & Touche LLP resigned as the Fund's independent auditor on September 6, 2023, citing an anticipated independence issue tied to a pending transaction between Tekla Capital Management LLC and abrdn Inc. The Board approved KPMG LLP as the Fund's auditor for the fiscal year ending September 30, 2023, on September 7, 2023. Shareholders should note the change comes from a transaction involving the Fund's adviser, though the filing reports no disagreements or reportable events with Deloitte.
Deloitte & Touche resigned September 6, 2023, due to an anticipated independence issue linked to the pending Tekla Capital Management and abrdn Inc. transaction
Audit Committee approved the resignation September 7, 2023; the Board approved KPMG LLP the same day for fiscal year ending September 30, 2023
Deloitte's reports for fiscal years ended September 30, 2022 and 2021 contained no adverse opinion, disclaimer, or qualification
No disagreements or reportable events with Deloitte were reported for those years or the interim period through September 6, 2023
The fund entered a distribution agreement dated December 14, 2022, with Foreside Fund Services, allowing it to sell common shares worth up to $150 million at market prices over time. Foreside has also engaged UBS Securities as a sub-placement agent for these sales. The filing does not report any shares sold yet, but future sales could add shares outstanding and raise capital for the fund.
Up to $150 million of common shares may be offered through Foreside Fund Services as agent, from time to time.
The fund pays Foreside a 1.00% commission on gross sale proceeds; Foreside pays UBS up to 0.80% of those proceeds.
Agreements are dated December 14, 2022, under a prospectus supplement and a shelf registration on Form N-2 (File No. 333-267555).
The fund may not sell shares below current net asset value, excluding distributing commissions or discounts.
Tekla World Healthcare Fund (NYSE: THW) introduced its first fact card, a summary of Fund information that may include quarterly data on performance, portfolio holdings, and geographic and sector allocations. The Fund intends to publish and distribute fact cards with quarterly data, so shareholders can review regular summary information about the Fund.
The fact card is available at www.teklacap.com or by request from Destra Capital Investments at (877) 855-3434.
The fact card may include quarterly data on performance, portfolio holdings, and geographic and sector information.
The Fund's investment adviser, Tekla Capital Management LLC, had approximately $2.9 billion of assets under management as of September 30, 2015.
The announcement was made in a press release dated October 19, 2015, filed as Exhibit 99.1.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every abrdn World Healthcare Fund filing is on SEC EDGAR ↗. 8-K briefs of other companies →